Will have to ask my dermatologist about this.

I am in a clinical trial study for nemolizumab (NEMO), I have been in it for over 2 years. It has worked very well for me. I have had PN since 2013 with severe symptoms of horrific sores and extreme itching. I have at the present time no sores or itching but lots of scars from the sores. This drug has been a blessing to me. I also had a friend with PN that was not as extreme as mine and it has helped her also. I highly recommend this treatment and hope it will help others as it has helped in.

ISNT Mast Cell Activation an inflammatory (autoimmune)problem and chief culprit is Interluken -31as wel as mentioned in PN?

Below is from the Internet, so definitely get more information from your dermatologist.

On February 14, 2024, the FDA accepted Galderma's Biologics License Application (BLA) for nemolizumab to treat prurigo nodularis and moderate to severe atopic dermatitis in adolescents and adults. The FDA also granted nemolizumab Priority Review for prurigo nodularis and Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis.

eMPR.com
Nemolizumab Under Review for Prurigo Nodularis, Atopic Dermatitis
Feb 14, 2024

Galderma
Galderma announces regulatory filing acceptance for nemolizumab in prurigo ...
Feb 14, 2024 — The U.S. Food and Drug Administration (FDA) has accepted Galderma's Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis. Nemolizumab was granted U.S. FDA Priority Review for prurigo nodularis. The European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. Further submissions to regulatory authorities in additional countries are planned in 2024.

Dermatology Times
FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis
Feb 14, 2024

MDedge
Company Announces Regulatory Filing for Nemolizumab for Two Indications | Clinician Reviews
Feb 20, 2024
Healio
FDA, EMA accept nemolizumab applications for prurigo nodularis, atopic dermatitis
Feb 14, 2024
Nemolizumab is a monoclonal antibody that inhibits interleukin (IL) IL-31 signaling. It's intended to provide safe and rapid relief from itch. The FDA has also accepted the European Medicines Agency's (EMA) Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis.
The application for the prurigo nodularis indication includes data from two phase 3 trials: OLYMPIA 1 and OLYMPIA 2. In both of the OLYMPIA trial programs, the subjects saw rates of 26% and 38% in OLYMPIA 1 and 2, respectively, compared to 7% and 11% among those given a placebo.

"Just keep swimming!"